Personalized Trial Ethics and Institutional Review Board Submissions.

Area of Science:

• Bioethics
• Clinical Research Regulation
• Personalized Medicine

Background:

• Traditional distinctions between clinical practice and research for human subjects oversight are increasingly criticized as outdated.
• Personalized trials present unique challenges due to their overlapping characteristics with both clinical practice and research.
• Current ethical and regulatory frameworks struggle to address the specific nature of personalized trials.

Purpose of the Study:

• To explore the ethical foundations of personalized trials.
• To propose adaptable regulatory approaches for personalized trials.
• To facilitate the integration of personalized trials into patient care.

Main Methods:

• Analysis of ethical principles governing clinical research and practice.
• Review of existing regulatory frameworks and their applicability to personalized trials.
• Development of a risk-based oversight model for personalized trials.

Main Results:

• Personalized trials require nuanced ethical and regulatory consideration beyond standard research models.
• A key factor for oversight is assessing the incremental increase in risk compared to usual care.
• Current regulations may pose unnecessary barriers to the adoption of personalized trials.

Conclusions:

• Ethical and regulatory oversight for personalized trials should be tailored to their specific risk profile.
• A risk-based approach, focusing on incremental participant risk, can reduce regulatory barriers.
• Promoting wider adoption of personalized trials requires adapting oversight to encourage innovation in individualized patient care.